

5
N-(4-methylbenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(3,4-dichlorobenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(furan-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(thiophen-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(2,3-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2,6-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine; or
N-(2,6-dichlorophenylacetyl)-N'-benzylguanidine; or a
pharmaceutically acceptable salt of any of said compounds.

REMARKS

Claims 1-6 were cancelled without prejudice, claims 10, 11, 19-24, 41, 44 and 45 were amended, and claims 46-77 have been added. No new matter has been added by virtue of the amendments. For instance, support for the amendments appears e.g. in the original claims of the application.

Claims 1-6, 10, 11, 19, 21, 22, 24 and 26-36 were rejected under the doctrine of improper Markush group.

The presented claims are fully acceptable under any asserted Markush doctrine. For instance, the claims have a "common core" of an carbonyl-substituted guanidino group. Withdrawal of the rejection is requested.

Claims 19 and 25-36 were rejected under 35 U.S.C. 112, fifth paragraph for improper multiple dependency.

The claim amendments made herein are believed to obviate this formalities-type matter. Withdrawal of the rejection is requested.

Claims 1-4, 19, 21, 22, 24, 26, and 28 were rejected under 35 U.S.C. 102 over Okajima et al., Fukada et al., Augustin et al., Gund et al., Malyuga et al., and Neidlen et al.

Claims 1-4, 19, 21, 22, 24, 26 and 27 were rejected under 35 U.S.C. 103 over Mulyuga et al.


For the sake of brevity, the Section 102 and 103 rejections are addressed in combination. Each rejection is traversed.

The cited documents clearly do not teach or suggest the claimed pending herein. Among other things, the cited documents do not suggest the therapeutic methods as claimed. Nor do the cited documents provide a suggestion of the pending compound claims, such as the cyclic compounds of claim 7.

In view thereof, reconsideration and withdrawal of the rejection are requested.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
P.O. Box 9169
Boston, Massachusetts 02209
(617) 523-3400

MARKED VERSION TO SHOW CHANGES

10. (amended) A compound [of claim 1, 7 or 9] that is:

N-(4-methylbenzoyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;
N-(4-methylbenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(4-methylbenzoyl)-N'-(1-naphthyl)guanidine;
N-(4-methylbenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(4-methylbenzoyl)-N'-(4-tertbutylphenyl)guanidine;
N-(4-methylbenzoyl)-1-indolinylicarboximidamide;
N-(4-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(4-methylbenzoyl)-1-[7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline] carboximidamide;
N-(4-methylbenzoyl)-1-(1,2,3,4-tetrahydroquinoline)carboximidamide;
N-(4-methylbenzoyl)-N'-(2,5-dibromophenyl)guanidine;
N-(4-methylbenzoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(4-methylbenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;
N-(4-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(4-tertbutylphenyl)guanidine;
N-(2,5-dichlorobenzoyl)-1-indolinylicarboximidamide;
N-(2,5-dichlorobenzoyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;
N-(phenylacetyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(phenylacetyl)-N'-(4-isopropylphenyl)guanidine;
N-(phenylacetyl)-N'-(4-tert-butylphenyl)guanidine;

N-(phenylacetyl)-1-indolinylicarboximidamide;
N-(phenylacetyl)-1-(1,2,3,4-tetrahydroquinoline)carboximidamide;
N-(phenylacetyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(phenylacetyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;
N-(adamantan-1-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(adamantan-1-carbonyl)-N'-(1-naphthyl)guanidine;
N-(adamantan-1-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)guanidine;
N-(adamantan-1-carbonyl)-N'-(4-tert-butylphenyl)guanidine;
N-(adamantan-1-carbonyl)-1-(indolinylicarboximidamide);
N-(adamantan-1-carbonyl)-1-(1,2,3,4-tetrahydroquinolinylicarboximidamide);
N-(adamantan-1-carbonyl)-N'-(2,5-dibromophenyl)guanidine;
N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;
N-(4-chlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(4-chlorobenzoyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;
N-(4-chlorobenzoyl)-N'-(1-naphthyl)guanidine;
N-(4-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(4-chlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(4-chlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;
N-(4-chlorobenzoyl)-1-(indolinylicarboximidamide);
N-(4-chlorobenzoyl)-1-(1,2,3,4-tetrahydroquinolinylicarboximidamide);
N-(4-chlorobenzoyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;
N-(3,4-dichlorobenzoyl)-1-(indolinylicarboximidamide);

N-(3,4-dichlorobenzoyl)-1-(1,2,3,4-tetrahydroquinoliny)l)carboximidamide;
N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;
N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(1-naphthyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;
N-(thiophen-2-carbonyl)-1-(indoliny)l)carboximidamide;
N-(thiophen-2-carbonyl)-1-(1,2,3,4-tetrahydroquinoliny)l)carboximidamide;
N-(thiophen-2-carbonyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;
N-(furan-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;
N-(furan-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;
N-(furan-2-carbonyl)-N'-(1-naphthyl)guanidine;
N-(furan-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;
N-(furan-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;
N-(furan-2-carbonyl)-1-(indoliny)l)carboximidamide;
N-(furan-2-carbonyl)-1-(1,2,3,4-tetrahydroquinoliny)l)carboximidamide;
N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;
N-(pyridin-3-carbonyl)-N'-(1-naphthyl)guanidine;
N-(pyridin-3-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(pyridin-3-carbonyl)-N'-(4-isopropylphenyl)guanidine;
N-(pyridin-3-carbonyl)-N'-(4-tert-butylphenyl)guanidine;
N-(pyridin-3-carbonyl)-1-(indoliny)l)carboximidamide;
N-(pyridin-3-carbonyl)-1-(1,2,3,4-tetrahydroquinoliny)l)carboximidamide;
N-(4-methoxybenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(4-methoxybenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;
N-(1-naphthoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(1-naphthoyl)-N'-(4-isopropylphenyl)guanidine;
N-(1-naphthoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(4-butoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(4-butoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(4-butoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;
N-(4-methylbenzoyl)-N'-(benzyl)guanidine;
N-(4-methylbenzoyl)-N'-(2-phenethyl)guanidine;
N-(4-methylbenzoyl)-N'-(3-dimethylaminopropyl)guanidine;
N-(4-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-methylbenzoyl)-N'-(1-naphthylmethyl)guanidine;
N-(4-methylbenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;
N-(4-methylbenzoyl)-N'-(5-phenylpentyl)guanidine;
N-(4-methylbenzoyl)-N'-(3-phenoxypropyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(benzyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-chlorobenzoyl)-N'-(benzyl)guanidine;
N-(4-chlorobenzoyl)-N'-(2-phenethyl)guanidine;
N-(4-chlorobenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-methoxybenzoyl)-N'-(benzyl)guanidine;
N-(4-methoxybenzoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenethyl)guanidine;
N-(4-methoxybenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-methoxybenzoyl)-N'-(2-(4-chlorophenylethyl)guanidine;
N-(4-methoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;
N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxybenzyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(2-phenethyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;
N-(4-butoxybenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-butoxybenzoyl)-N'-(2-phenethyl)guanidine;
N-(4-butoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;
N-(4-butoxybenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-butoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-(2-phenylethyl)guanidine;
N-(1-naphthoyl)-N'-(benzyl)guanidine;
N-(1-naphthoyl)-N'-(3-dimethylaminopropyl)guanidine;
N-(1-naphthoyl)-N'-(2-phenylethyl)guanidine;
N-(1-naphthoyl)-N'-(4-phenylbutyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(benzyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(3-dimethylaminopropyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(2-phenylethyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(4-phenylbutyl)guanidine;
N-(4-methylbenzoyl)-N'-(cyclohexyl)-N''-methylguanidine;
N-(4-methylbenzoyl)-N'-(4-phenylbutyl)-N''-methylguanidine;

N-(4-methoxybenzoyl)-N'-(5-phenylpentyl)guanidine;
N-(2-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(2-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(2-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-methoxybenzoyl)-N'-(2-phenoxypropyl)guanidine;
N-(4-butoxybenzoyl)-N'-(5-phenylpentyl)guanidine;
N-(4-methylbenzoyl)-N'-(2-phenoxyethyl)guanidine;
N-(4-methoxybenzoyl)-N'-(2-phenoxyethyl)guanidine;
N-(4-ethoxybenzoyl)-N'-[(2-benzylthio)ethyl]guanidine;
N-(4-ethoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;
or a pharmaceutically acceptable salt of any of said compounds.

11. (amended) A compound [of any of claims 1, 7 or 9] that is:

N-(2-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(2-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;
N-benzoyl-N'-(4-isopropylphenyl)guanidine;
N-benzoyl-N'-(4-isopropoxyphenyl)guanidine;
N-benzoyl-N'-(4-benzyloxyphenyl)guanidine;
N-benzoyl-N'-(2-isopropylphenyl)guanidine;
N-(2,6-dichlorophenacetyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(2,6-dichlorophenacetyl)-N'-(phenyl)guanidine;
N-(2,6-dichlorophenacetyl)-N'-(4-isopropyl)phenylguanidine;
N-(2,6-dichlorophenacetyl)-1-(indoliny)carboxamidamide;
N-(2-chlorobenzoyl)-N'-(4-isopropyl)phenylguanidine;
N-(2-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(2-chlorobenzoyl)-1-(indoliny)carboxamidamide;

N-(2,6-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(2,6-dichlorobenzoyl)-N'-(2-isopropylphenyl)guanidine;
N-(2,6-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(2,6-dichlorobenzoyl)-1-(indolyl)carboxamidamide;
N-(2,6-dichlorobenzoyl)-N'-(trimethoxyphenyl)guanidine;
N-(2,3-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;
N-(2,3-dichlorobenzoyl)-1-(indolyl)carboxamidamide;
N-(2,3-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;
N-(4-methoxybenzoyl)-N'-(5-phenylpentyl)guanidine;
N-(2-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;
N-(4-methoxybenzoyl)-N'-(3-phenoxypropyl)guanidine;
N-(4-butoxybenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(4-methoxybenzoyl)-N'-(3-phenoxyethyl)guanidine;
N-(4-ethoxybenzoyl)-N'-(3-benzylthioethyl)guanidine;
N-benzoyl-N'-(4-phenylbutyl)guanidine;
N-benzoyl-N'-(3-phenoxypropyl)guanidine;
N-benzoyl-N'-(3,4,5-trimethoxybenzyl)guanidine;
N-benzoyl-N'-(2-benzylthioethyl)guanidine;
N-(4-methylbenzoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;
N-(4-chlorobenzoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;
N-(1-naphthoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;
N-(thiophen-2-carbonyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;
N-(4-methylbenzoyl)-N'-butylguanidine;
N-(furan-2-carbonyl)-N'-(3-phenylpropyl)guanidine;
N-(4-methylbenzoyl)-N'-(2-benzylthioethyl)guanidine;
N-(4-methylbenzoyl)-N'-(1-indanyl)guanidine;
N-(N-(4-chlorobenzoyl)-N'-(1-indanyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(1-indanyl)guanidine;
N-(1-naphthoyl)-N'-[(imidazol-1-yl)-3-propyl]guanidine;
N-(furan-2-carbonyl)-N'-[(imidazol-1-yl)-3-propyl]guanidine;
N-(4-chlorobenzoyl)-N'-(2-benzylthioethyl)guanidine;
N-(3,4-dichlorobenzoyl)-N'-(2-benzylthioethyl)guanidine;
N-(1-naphthoyl)-N'-(2-benzylthioethyl)guanidine;
N-(thiophen-2-carbonyl)-N'-(2-benzylthioethyl)guanidine;
N-(4-methylbenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(3,4-dichlorobenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(3,4,5-trimethoxybenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(furan-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(thiophen-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;
N-(2,3-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2,5-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine;
N-(2,6-dichlorobenzoyl)-N'-(4-phenylbutyl)guanidine; or
N-(2,6-dichlorophenylacetyl)-N'-benzylguanidine; or a
pharmaceutically acceptable salt of any of said compounds.

19. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms.

20. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is optionally substituted cyclic alkyl.

21. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is optionally substituted carbocyclic aryl.

22. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is optionally substituted phenyl or naphthyl.

23. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is optionally substituted heteroaromatic or heteroalicyclic.

24. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 10-18] wherein R is optionally substituted carbocyclic aralkyl.

26. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 12-25] wherein at least one R¹ group is hydrogen.

27. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 12-25] wherein both R¹ groups are hydrogen.

28. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 12-25] wherein at least one R¹ group is optionally substituted alkyl.

29. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 12-25] wherein at least one R¹ group is alkyl having 1 to 3 carbon atoms.

30. (amended) A compound of any one of claims 7-9 or 12-18 [1-9 or 12-25] wherein both R¹ groups are optionally substituted alkyl.

31. (amended) A method of treating a nerve degeneration disease comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18 [1-30].

32. (amended) A method of treating a neurodegenerative disease comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18 [1-30].

33. (amended) A method of treating Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome or Korsakoff's disease, Cerebral Palsy, or epilepsy, comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18 [1-30].

34. (amended) A method of treating or preventing nerve cell death or degeneration comprising administering to a mammal suffering from or susceptible to nerve cell death or degeneration a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

36. (amended) A method of treating a mammal suffering from or susceptible to stroke or heart attack comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

37. (amended) A method of treating a mammal suffering from or susceptible to brain or spinal cord trauma comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

38. (amended) A method of treating a mammal suffering from or susceptible to pain including chronic pain or neuropathic pain, peripheral neuropathy, migraines, shingles, emesis, narcotic withdrawal symptoms or age-dependent dementia, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

39. (amended) A method of treating a mammal suffering from or susceptible decreased blood flow or nutrient supply to retinal tissue or optic nerve, or retinal ischemia or trauma, or optic nerve injury, or glaucoma, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

40. (amended) A method of treating a mammal suffering from or susceptible to post-surgical neurological deficits or neurological deficits associated with cardiac arrest, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18 [1-30].

41. (amended) A method for treating an infection in a mammal, comprising administering to a mammal suffering from or susceptible to an infection an effective amount of an aminoglycoside antibiotic and a compound of any one of claims 7-8 or 12-18 [1-30].

44. (amended) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of any one of claims 1-3, 7-8 or 12-18 [1-30] and a pharmaceutically acceptable carrier.

45. (amended) A compound of any one of claims 1-3, 7-8 or 12-18 [1-30] that is radiolabelled.